Date: 2016-01-13
Type of information: Company acquisition
Acquired company: Sinensis Life Sciences (The Netherlands)
Acquiring company: Eurofins Scientific (Luxembourg)
Amount: undisclosed
Terms: * On January 13, 2016, Eurofins Scientific announced the acquisition of Sinensis Life Sciences, a leading provider of pharmaceutical product testing and cGMP Quality Control (QC) services in the Netherlands. Since inception, Sinensis has consistently grown well above Eurofins’ annual organic growth objective, and expects to generate revenues in excess of € 13.5m for 2015, the majority of which from biopharmaceutical products testing. Sinensis’ competencies are consistent with Eurofins’ market-leading biopharmaceutical testing capabilities, and specifically with the competencies of Eurofins Lancaster, the global reference in biopharmaceutical testing. Therefore, the acquisition strengthens the Group’s geographical footprint and its position as the market leader in this stable and consistently growing pharmaceutical services segment. Furthermore, this acquisition reinforces the Group’s platform to further accelerate the deployment of the most advanced testing methodologies to support the pharmaceutical and biotechnology industries across the entire drug development cycle in Europe.
Details: Sinensis Life Sciences is a provider of pharmaceutical product testing and cGMP Quality Control services in the Netherlands. Sinensis is the reference laboratory for both microbiology and chemistry testing for biopharmaceutical products in the domestic market, and has a presence in Europe, Asia and the US. The company employs about 150 staff, serving the pharmaceutical and biotechnology industries throughout the Netherlands. The company is also active in biosafety testing and biological R&D, chemical R&D, and in cGMP manufacturing.
Related: Analytical services
